Massachusetts is arguing in court that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a drug, in this case barring use of Zogenix Inc.’s opioid Zohydro ER (hydrocodone extended-release).
Last month Massachusetts Gov. Deval Patrick issued an emergency ban on the prescribing and dispensing of Zohydro ER until the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?